These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 18245967)

  • 1. Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers.
    Holland EJ; Bartlett JD; Paterno MR; Usner DW; Comstock TL
    Cornea; 2008 Jan; 27(1):50-5. PubMed ID: 18245967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension in pediatric subjects.
    Comstock TL; Paterno MR; Bateman KM; Decory HH; Gearinger M
    Paediatr Drugs; 2012 Apr; 14(2):119-30. PubMed ID: 22292487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability of loteprednol/tobramycin versus dexamethasone/tobramycin in healthy volunteers: results of a 4-week, randomized, double-masked, parallel-group study.
    Bartlett JD; Holland EJ; Usner DW; Paterno MR; Comstock TL
    Curr Med Res Opin; 2008 Aug; 24(8):2219-27. PubMed ID: 18577309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraocular pressure elevations with loteprednol etabonate: a retrospective chart review.
    Rajpal RK; Digby D; D'Aversa G; Mah F; Hollander DA; Conway T
    J Ocul Pharmacol Ther; 2011 Jun; 27(3):305-8. PubMed ID: 21574815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis.
    Chen M; Gong L; Sun X; Gu Y; He X; Qu J; Wang L; Zhang M; Zhong X
    Curr Med Res Opin; 2012 Mar; 28(3):385-94. PubMed ID: 22256909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis.
    White EM; Macy JI; Bateman KM; Comstock TL
    Curr Med Res Opin; 2008 Jan; 24(1):287-96. PubMed ID: 18062846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation.
    Holland EJ; Djalilian AR; Sanderson JP
    Cornea; 2009 Dec; 28(10):1139-43. PubMed ID: 19770719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Change in intraocular pressure during long-term use of loteprednol etabonate.
    Novack GD; Howes J; Crockett RS; Sherwood MB
    J Glaucoma; 1998 Aug; 7(4):266-9. PubMed ID: 9713785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance.
    Pflugfelder SC; Maskin SL; Anderson B; Chodosh J; Holland EJ; De Paiva CS; Bartels SP; Micuda T; Proskin HM; Vogel R
    Am J Ophthalmol; 2004 Sep; 138(3):444-57. PubMed ID: 15364229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis.
    Shulman DG; Lothringer LL; Rubin JM; Briggs RB; Howes J; Novack GD; Hart K
    Ophthalmology; 1999 Feb; 106(2):362-9. PubMed ID: 9951491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis.
    Ilyas H; Slonim CB; Braswell GR; Favetta JR; Schulman M
    Eye Contact Lens; 2004 Jan; 30(1):10-3. PubMed ID: 14722462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled trial comparing dexamethasone with loteprednol etabonate on postoperative photorefractive keratectomy.
    Thanathanee O; Sriphon P; Anutarapongpan O; Athikulwongse R; Thongphiew P; Rangsin R; Suwan-apichon O
    J Ocul Pharmacol Ther; 2015 Apr; 31(3):165-8. PubMed ID: 25555173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery.
    Rajpal RK; Roel L; Siou-Mermet R; Erb T
    J Cataract Refract Surg; 2013 Feb; 39(2):158-67. PubMed ID: 23218817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The conjunctival provocation test model of ocular allergy: utility for assessment of an ocular corticosteroid, loteprednol etabonate.
    Abelson M; Howes J; George M
    J Ocul Pharmacol Ther; 1998 Dec; 14(6):533-42. PubMed ID: 9867336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loteprednol Etabonate 0.5% Gel Vs. Prednisolone Acetate 1% Solution After Descemet Membrane Endothelial Keratoplasty: Prospective Randomized Trial.
    Price MO; Feng MT; Scanameo A; Price FW
    Cornea; 2015 Aug; 34(8):853-8. PubMed ID: 26020827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steroid-induced ocular hypertension with loteprednol etabonate 0.2%--a case report.
    Lu E; Fujimoto LT; Vejabul PA; Jew RL
    Optometry; 2011 Jul; 82(7):413-20. PubMed ID: 21543264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model.
    Berdy GJ; Stoppel JO; Epstein AB
    Clin Ther; 2002 Jun; 24(6):918-29. PubMed ID: 12117082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery.
    Lane SS; Holland EJ
    J Cataract Refract Surg; 2013 Feb; 39(2):168-73. PubMed ID: 23232255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of tobramycin 0.3%/dexamethasone 0.1% and tobramycin 0.3%/loteprednol 0.5% in the management of blepharo-keratoconjunctivitis.
    Rhee SS; Mah FS
    Adv Ther; 2007; 24(1):60-7. PubMed ID: 17526462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure.
    Sheppard JD; Comstock TL; Cavet ME
    Adv Ther; 2016 Apr; 33(4):532-52. PubMed ID: 26984315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.